贫血在结外鼻型NK/T细胞淋巴瘤预后价值——中国淋巴瘤放疗协作组多中心研究

doi:10.3760/cma.j.issn.1004-4221.2018.02.007

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To evaluate the prognostic value of anemia in patients diagnosed with extranodal nasal-type natural killer (NK)/T cell lymphoma (NKTCL). Methods Clinical data of 1225 NKTCL patients receiving the first course of treatment from 10 medical institutions in China were retrospectively analyzed. According to the diagnostic criteria in China, anemia was defined as the hemoglobin (Hb) level< 120 g/L for the male and< 110 g/L for the female from the sea-level area. The severity of anemia was classified into the extremely severe anemia (Hb ≤ 30 g/L), severe anemia (31-60 g/L), moderate anemia (61-90 g/L) and mild anemia (>90 g/L). Results Among 1225 patients, 199(16.2%) were complicated with anemia, who had more adverse prognostic factors compared with their counterparts without anemia. Among NKTCL patients with anemia, the proportion of patients with stage Ⅱ-IV, a median age> anemia, Eastern Cooperative Oncology Group (ECOG) score of 2-4 and NK/T-cell lymphoma prognostic index (NKTCLPI) ≥ 2 was relatively high. Patients with anemia obtained worse clinical prognosis than those without anemia. The 5-year overall survival (OS) and progression-free survival (PFS) in NKTCL patients with anemia were calculated as 49.4% and 35.4%, significantly lower compared with 63.3% and 56.0% in their counterparts without anemia (both P<0.01). Single factor analysis demonstrated that anemia, age, ECOG score, group B symptom, lactate dehydrogenase, primary tumor site, primary tumor invasion and staging were the prognostic factors of OS and PFS. Multivariate analysis revealed that anemia was still the independent prognostic factor. Conclusions Anemia is not common in patients with NKTCL and these patients obtain poor clinical prognosis. Anemia is an independent prognostic factor for patients with NKTCL.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Fang Hui
	Zhu Suyu
	Xu Liming
	Wang Peiguo
	Wu Tao
	Qian Liting
	Zhang Fuquan
	Hou Xiaorong
	Qi Shunan
	Yang Yong
	Jin Jing
	Zhang Yujing
	Zhu Yuan
	Cao Jianzhong
	Lan Shengmin
	Wu Junxin
	Li Yexiong

Key words： Lymphoma,extranodal NK/T cell Lymphoma,nasal-type Anemia Prognosis

Received: 28 August 2017

Fund:National Key Projects of Research and Development (2016YFC0904600);Medical and Health Science and Technology Innovation Project of Chinese Academy of Medical Sciences (2016-I2M-1-001)

Corresponding Authors: Li Yexiong,Email:yexiong12@163.com

About author:: Fang hui and Zhu Suyu for the common first author

Cite this article:

Fang Hui,Zhu Suyu,Xu Liming et al. Prognostic value of anemia in patients with extranodal nasal-type NK/T cell lymphoma:A multi-center study from CLROG[J]. Chinese Journal of Radiation Oncology, 2018, 27(2): 155-160.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2018.02.007 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2018/V27/I2/155

[1] Ai WZ,Chang ET,Fish K,et al. Racial patterns of extranodal natural killer/T-cell lymphoma,nasal type,in California:a populationbased study[J],Brit J Haematol,2012,156(3):626-632.
[2] Au WY,Weisenburger DD,Intragumtornchai T,et al. International Peripheral TCLP:Clinical differences between nasal and extranasal natural killer/T-cell lymphoma:a study of 136 cases from the International Peripheral T-Cell Lymphoma Project[J].Blood,2009,113(44):3931-3937.
[3] Suzuki R,Suzumiya J,Yamaguchi M,et al. Prognostic factors for mature natural killer (NK) cell neoplasms:aggressive NK cell leukemia and extranodal NK cell lymphoma,nasal type[J] Ann Oncol,2010,21(5):1032-1040.DOI:10.1093/annonc/mdp418.
[4] Kim TM,Lee SY,Jeon YK,et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma,nasal type:a national survey of the Korean Cancer Study Group[J].Ann Oncol,2008,19(8):1477-1484.DOI:10.1093/annonc/mdn147.
[5] Vazquez A,Khan MN,Blake DM,et al. Extranodal natural killer/T-Cell lymphoma:A population-based comparison of sinonasal and extranasal disease[J].Laryngoscope,2014,124(?):888-895.DOI:10.1002/lary.24371.
[6] Li YX,Yao B,Jin J,Wang WH,et al. Radiotherapy as primary treatment for stage ⅠE and ⅡE nasal natural killer/T-cell lymphoma[J].J Clin Oncol,2006,24(1):181-189.
[7] Yang Y,Zhu Y,Cao JZ,et al. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma:analysis from a multicenter study[J]. Blood,2015,126(6):1424-1432.
[8] Yang Y,Zhang YJ,Zhu Y,et al. Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma,nasal-type:a multicenter study[J].Leukemia,2015,29(7):1571-1577.
[9] 亓姝楠,徐利明,袁志勇,等.原发肿瘤负荷对结外鼻型NK/T细胞淋巴瘤预后影响[J].中华放射肿瘤学杂志,2017,26(5):532-537.
Qi SN,Xu LM,Yuan ZY,et al. Prognostic role of primary tumor burden in extranodal nasal-type NK/T-cell lymphoma[J].Chin J Radiat Oncol,2017,26(5):532-537.DOI:.DOI:10.3760/cma.j.issn.1004-422102015.04.006.
[10] 牛绍清,张玉晶,温戈,等.早期原发鼻腔NK/T细胞淋巴瘤局部扩大野IMRT前瞻性Ⅱ期研究的初步结果[J].中华放射肿瘤学杂志,2015,24(4):377-381.DOI:10.3760/cma.j.issn.1004-422102015.04.006.Niu SQ,Zhang YJ,温Wen G,et al. Preliminary results of a phase Ⅱ prospective clinical study of early-stage nasal NK/T-cell lymphoma with extended involved-field intensity-modulated radiotherapy[J].Chin J Radiat Oncol,2015,24(4):377-381.DOI:?.
[11] Moullet I,Salles G,Ketterer N,et al. Frequency and significance of anemia in non-Hodgkin’s lymphoma patients[J].Ann Oncol,1998,9(5):1109-1115.
[12] Ludwig H,Van Belle S,Barrett-Lee P,et al. The European Cancer Anaemia Survey (ECAS):a large,multinational,prospective survey defining the prevalence,incidence,and treatment of anaemia in cancer patients[J].Eur J Cancer,2004,40(15):2293-2306.
[13] 潘湘涛,陆晔,程旭,等.癌症患者治疗前后血红蛋白变化及贫血发生情况的调查分析[J].中华肿瘤防治杂志,2008,15(20):1540-1543.Pan XT,Lu Y,Cheng X,et al. Investigation and analysis of hemoglobin changes and anemia in cancer patients before and after treatment[J].Chin J Cancer Prevent Treat,2008,15(20):1540-1543.
[14] Yang Y,Cao JZ,Lan SM,et al. Association of improved locoregional control with prolonged survival in early-stage extranodal nasal-type NK/T-cell lymphoma[J].JAMA Oncol,2017,3(1):83-91.DOI:10.1001/jamaoncol.2016.5094
[15] Hong J,Woo HS,Kim H,et al. Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-C HOP immunochemotherapy[J]. Cancer Sci,2014,105(12):1569-1575.DOI:10.1111/cas.12544.
[16] Adams HJ,Klerk JM,Fijnheer R,et al. Prognostic value of anemia and c-reactive protein levels in diffuse large B-cell lymphoma[J].Clin Lymphoma Myeloma Leuk,2015,15(11):671-679.DOI:10.1016/j.clml.2015.07.639.
[17] 黄晓东,易俊林,高黎,等.放疗前贫血对鼻咽癌预后的影响[J].中华放射肿瘤学杂志,2006,15(2):73-76.Huang XD,Yi JL,Gao L,et al. Effect of preoperative anemia on prognosis of nasopharyngeal carcinoma[J].Chin Radiat Oncol,2006,15(2):73-76.
[18] 潘建基,张瑜,林少俊,等.1706例鼻咽癌放疗远期疗效分析[J].中华放射肿瘤学杂志,2008,17(4):247-251.Pan JJ,Zhang Y,Lin SJ,et al. Long-term efficacy of radiotherapy for 1706 cases of nasopharyngeal carcinoma[J].Chin J Radiat Oncol,2008,17(4):247-251.
[19] Caro JJ,Salas M,Ward A,et al. Anemia as an independent prognostic factor for survival in patients with cancer[J].Cancer,2001,91(13):2214-2220.
[20] Engert A,Josting A,Haverkamp H,et al. Epoetin Alfa in Patients with advanced-stage Hodgkin’s lymphoma:results of the randomized placebo-controlled GHSG HD15 EPO trial[J].J Clin Oncol,2010,28(13):2239-2245.DOI:10.1200/JCO.2009.25.1835.
[21] Hoskin PJ,Robinson M,Slevin N,et al. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer[J].J Clin Oncol,2009,27(34):5751-576.DOI:10.1200/JCO.2009.22.3693.
[22] Morrow TJ,Volpe S,Gupta S,et al. Anemia of cancer in intermediate-grade non-Hodgkin′s lymphoma[J].South Med J, 2002,95(8):889-896.